CEO Executive AssistantPublications strategy and medical writing are foundational to how a pharmaceutical company builds the scientific evidence base for its products, engages with the clinical community, and supports regulatory submissions. Despite this importance, these functions are frequently under-resourced, loosely governed, and poorly integrated with the broader commercial and regulatory strategy. For pharma CEOs, the delegation challenge is ensuring that medical writing and publications are strategically managed without becoming personally involved in the production of scientific content.
This guide outlines how pharma CEOs can build an effective delegation framework for medical writing and publications strategy, covering governance structures, accountability models, and the specific points where CEO involvement adds genuine value.
The Strategic Importance of Publications
Publications in peer-reviewed journals serve multiple strategic purposes for pharmaceutical companies. They establish the scientific credibility of clinical evidence for a product. They influence physician prescribing behavior through data presentation and interpretation. They support regulatory submissions with published evidence of efficacy and safety. And they are a primary vehicle for engaging key opinion leaders through collaborative authorship and data presentation opportunities.
A publications program that is fragmented, delayed, or strategically misaligned with commercial and regulatory needs represents a real competitive disadvantage. The CEO does not need to manage publications directly, but should ensure that the company has a publications infrastructure that is operating as a strategic asset.
Mapping the Publications and Medical Writing Ecosystem
Before delegating effectively, the CEO needs to understand the range of activities that fall under medical writing and publications:
Regulatory medical writing includes the preparation of clinical study reports (CSRs), summary documents for regulatory submissions (Module 2 and Module 5 content), investigational new drug applications, and regulatory responses. This is a specialized technical function that requires expertise in regulatory writing conventions and ICH guidelines.
Publications strategy covers the planning and execution of the company’s scientific publication program, including deciding which data to publish, in which journals, on what timelines, and with which authors. This is a strategic function that requires alignment with commercial, regulatory, and medical affairs.
Publication execution covers the actual drafting, revision, and submission of manuscripts, abstracts, and posters for scientific journals and congresses. This execution work may be done by internal medical writers, by external medical writing agencies, or by academic author-writers, depending on the company’s model.
Congress and symposia planning covers the development of content for medical congress presentations, satellite symposia, and medical education events. This is closely related to publications but is more directly oriented toward KOL engagement and immediate clinical community communication.
The Delegation Architecture for Medical Writing and Publications
Chief Medical Officer or VP of Medical Affairs
The primary owner of publications strategy and medical writing governance is the CMO or VP of Medical Affairs. This individual is accountable for ensuring that the publications program is strategically aligned, adequately resourced, compliant with Good Publication Practice (GPP) guidelines and legal requirements, and effectively supporting the company’s commercial and regulatory objectives.
The CEO should hold the CMO accountable for publications performance through structured reporting rather than reviewing publications content directly.
Head of Publications or Publications Director
A dedicated publications leader is responsible for the operational management of the publications program: maintaining the publications plan, coordinating with clinical, regulatory, and commercial stakeholders on publication priorities, managing author relationships, working with external agencies, and tracking submission and publication timelines.
This role sits within medical affairs and reports to the CMO or VP of Medical Affairs. The CEO should know this role exists and that it is adequately resourced, but should not manage it directly.
Regulatory Medical Writing function
Regulatory medical writing is typically a distinct organizational capability from publications, reflecting the different skills, guidelines, and stakeholders involved. It may sit within regulatory affairs or as a shared service. This function should have clear accountability for delivering regulatory writing outputs on schedule and to quality standards, with reporting to the Head of Regulatory Affairs.
External medical writing agencies
Most pharma companies rely on a combination of internal medical writers and external agencies. Managing agency relationships (vendor selection, quality oversight, contracting, and performance management) belongs to the publications and regulatory writing functions, not to the CEO.
What the CEO Should and Should Not Own in Publications
The CEO should not be involved in decisions about which journals to target, how manuscripts are structured, which data analyses are included in a publication, or what language is used to describe study results. These are scientific and strategic decisions that belong to the medical affairs and publications functions.
The CEO should be involved in:
Publications as a strategic priority. If the company’s publications program is chronically under-resourced or is not being treated with the strategic seriousness its impact deserves, the CEO must make it a priority and provide the necessary investment. This is a resource allocation and organizational culture decision that starts at the CEO level.
Major strategic publications decisions. For landmark studies that will define the company’s clinical narrative (pivotal trial publications, major outcomes studies), the CEO should be aware of the publication timeline and strategy. These publications often have investor and regulatory implications that make them CEO-relevant even if the content decisions belong to medical affairs.
Compliance with Good Publication Practice. The CEO should understand that the company has policies requiring compliance with GPP guidelines, including disclosure of company involvement in publications, transparency about data in pooled analyses, and appropriate authorship attribution. The CEO should back the compliance and legal functions in enforcing these standards even when they create friction with external authors or investigators.
Structuring the Publications Governance System
Effective publications governance requires a publications steering committee or equivalent body that aligns publication priorities across clinical, regulatory, medical affairs, and commercial functions. This committee reviews the annual publications plan, resolves prioritization conflicts, and ensures that publication timelines are aligned with regulatory submissions and commercial launch calendars.
The publications committee should be chaired by the CMO or VP of Medical Affairs and should include representation from regulatory affairs, commercial, and legal. The CEO should receive a summary of the annual publications plan and any major publications strategy decisions from this committee, but should not chair or attend these meetings routinely.
Managing the Interface Between Publications and Regulatory
One of the most important coordination challenges in pharma publications management is ensuring that the publications timeline is aligned with the regulatory submission strategy. Publishing clinical data before it has been submitted to regulatory agencies can create complications if published results differ from the regulatory submission data. Conversely, delaying publications for regulatory reasons can frustrate academic collaborators and be perceived as publication bias.
The regulatory affairs and publications functions should have a documented protocol for managing the interface between regulatory submissions and publications, including a standard review process that ensures regulatory leadership awareness of planned publications for key study data. The Head of Regulatory Affairs and the VP of Medical Affairs are jointly accountable for managing this interface.
The CEO does not need to be involved in individual publication-regulatory coordination decisions, but should ensure that the governance protocol exists and is being followed.
Addressing Publication Bias and Compliance Risks
Selective publication, ghost-writing, and inappropriate authorship are areas where pharma companies have faced significant reputational and legal consequences. The CEO should treat compliance with Good Publication Practice as a genuine priority rather than a box-checking exercise.
This means: ensuring the publications function has clear policies aligned with ICMJE, GPP4, and other relevant guidelines; backing the legal and compliance functions when they raise concerns about proposed publication practices; and being willing to accept delays or modifications to publication plans when compliance concerns are identified.
The CEO should receive an annual compliance report from the publications and legal functions on the state of publications compliance, including any issues identified and resolved during the year.
For broader context on managing the medical affairs function from which publications strategy flows, see the digital health delegation guide for perspectives on managing scientific innovation functions. For the regulatory interface with medical writing, the regulatory affairs guide covers relevant governance frameworks.
Investing in Medical Writing Capability
Medical writing is a specialized skill that many pharma companies undervalue. Experienced regulatory medical writers and publications writers are genuinely scarce, and the quality of their work directly affects the clarity of clinical evidence presentations, the efficiency of regulatory submissions, and the scientific credibility of the publications program.
Pharma CEOs should ensure that the medical writing function is adequately resourced, that compensation levels are competitive enough to attract experienced writers, and that the function has access to appropriate technology (electronic regulatory submission systems, publications management software) to work efficiently.
The practical implication for the CEO is to support the CHRO and CMO in treating medical writing as a priority capability in talent planning and compensation benchmarking, not as an administrative support function.
Congress Planning and Scientific Communication
Medical congress planning, including abstract submissions, poster presentations, and oral presentations, is closely related to publications strategy and is typically managed by the publications and medical education functions within medical affairs.
The CEO’s involvement in congress planning should be limited to: awareness of the company’s presence and key data presentations at major congresses in the therapeutic areas of greatest strategic importance; decisions about whether to sponsor symposia at major congresses (these are significant investment decisions); and, for pivotal trial presentations, personal attendance at the session where possible if the trial result is commercially significant.
Day-to-day congress planning, abstract submission, and logistics are fully delegated functions.
Building Accountability Through Metrics
Publications strategy is a function where many pharma companies lack the performance metrics needed to hold the function accountable. The CEO should expect the CMO to report on publications performance metrics including:
Number of publications and abstracts per year against plan, time from study completion to primary publication, publication rate for completed studies across the portfolio, citations and reach metrics for key publications, and any compliance deviations in the publications program.
These metrics allow the CEO to hold the medical affairs function accountable for publications performance without managing the function directly.
Conclusion
Medical writing and publications strategy is a domain where effective CEO delegation, combined with strong medical affairs leadership and appropriate governance structures, produces a significant organizational capability advantage. By establishing clear ownership, building the governance infrastructure, ensuring adequate resource investment, and maintaining compliance as a genuine priority, pharma CEOs can build publications programs that meaningfully contribute to the company’s scientific credibility, regulatory success, and commercial performance, without requiring CEO involvement in the day-to-day production of scientific content.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.